overview of postmarketing drug safety reporting requirements - redi 2020
Published 3 years ago • 5.9K plays • Length 35:16Download video MP4
Download video MP3
Similar videos
-
14:52
postmarketing safety and surveillance of generic drugs update
-
36:51
investigational new drug safety reporting requirements (10of14) redi 2018
-
56:41
postmarket safety surveillance: tools, methods, and benefit-risk framework - pharmacovigilance 2020
-
59:01
postmarketing drug safety compliance: 2019 inspection findings
-
48:21
fda adverse event reporting system (faers) overview - pharmacovigilance 2020
-
21:20
investigator responsibilities - safety reporting for investigational drugs and devices
-
29:21
preventing medication errors: lessons learned from postmarket safety surveillance– pharmacovigilance
-
41:06
division of risk management: overview of review activities and rems - pharmacovigilance 2020
-
1:10:40
bimo, rems, and pade inspection readiness (3of3) jun. 19, 2018
-
27:21
digital ind safety reporting - pharmacovigilance 2020
-
58:43
so, your nda was approved – now what?! post-approval responsibilities and obligations- redi 2020
-
27:10
overview of post-approval chemistry, manufacture, and controls (cmc) changes to an nda - redi 2020
-
52:33
fda drug manufacturing inspections - redi 2020
-
38:38
enhanced drug distribution security – dscsa implementation updates - redi 2020
-
35:38
safety reporting requirements and safety assessment for ind and ba/be studies
-
54:27
fda's sentinel initiative - pharmacovigilance 2020
-
23:33
combination products: reporting device information and malfunctions - pharmacovigilance 2020
-
36:55
components of new drug application and biologics license application (5of15) redi– may 29-30, 2019
-
38:16
considerations for rems surveys and assessments: planning and reporting - pharmacovigilance 2020